Bristol-Myers Squibb Company
SELECTIVE NR2B ANTAGONISTS
Last updated:
Abstract:
The present disclosure provides compounds of Formula (I) and pharmaceutically acceptable salts thereof. The Formula (I) compounds are ligands for NR2B N-Methyl-D-aspartate (NMDA) receptor and thereby making them useful for the treatment of various disorders of the central nervous system. ##STR00001##
Status:
Application
Type:
Utility
Filling date:
9 Dec 2019
Issue date:
16 Apr 2020